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A Comment on Marschall et al
To the Editor—We read with interest
the recent article by Marschall et al [1]
on the impact of prebiopsy antibiotics
on pathogen recovery in hematoge-
nous vertebral osteomyelitis. The authors
found that antibiotic therapy before
diagnostic biopsy for vertebral osteomye-
litis did not affect the microbiologic yield
of an open bone biopsy. The authors ac-
knowledge some limitations; for example,
the higher diagnostic yield may have re-
flected the fact that patients with more
extensive infection were more likely to
require surgery, leading to improved
sampling and presumably higher bacterial
load.
The main goals of diagnostic evalua-
tion for spinal osteomyelitis are to iden-
tify the causative microorganism and
determine the extent of infection. Micro-
biologic diagnosis through computed
tomography–guided percutaneous biopsy
or open biopsy is essential for the man-
agement and pathogen-specific therapy of
such severe infections. In the study of
Marschall et al [1], methicillin-resistant
Staphylococcus aureus (MRSA) was the
predominant pathogen recovered from
biopsy specimens, and vancomycin was
the antibiotic most frequently used before
biopsy. In our view, these findings are
relevant for the interpretation of this
study. MRSA is not rapidly killed by
vancomycin [2], and therefore the appli-
cation of vancomycin before biopsy is
unlikely to sterilize the culture and explain
the results. However, other bacteria, such
as streptococci [3, 4], are highly suscepti-
ble to b-lactams, and cultures negative for
streptococci after initiation of antimicro-
bial treatment are common. In this con-
text, antibiotics had to be discontinued
at least 14 days before biopsy to optimize
the microbiologic yield for diagnosis of
device-associated osteomyelitis [5].
For these reasons, the data presented
by Marschall et al [1] have to be in-
terpreted with caution and may not
be generalizable to settings where the
prevalence of MRSA and use of vamco-
mycin is less frequent. Obtaining biopsy
specimens before initiating empirical
antibiotic treatment should remain the
state of the art [6].
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